Jakavi GvHD
In GvHD, JAKAVI provides rapid and best overall response, symptom improvement sustained failure-free survival vs Best Available Therapy4
The day you choose JAKAVI is the day you could change their story*3
In acute GvHD, JAKAVI provides
- Improved overall survival5
- Enhanced overall response rate (ORR)5
- Reduced signs and symptoms3
- Consistent safety with observations4
In chronic GvHD, JAKAVI provides
- Reduced signs and symptoms3
- Enhanced overall response4
- Extended patients’ failure-free survival vs Control**
- Consistent safety with expectations4
SVG
| 2024 EBMT Guidelines: Ruxolitinib is a recommended therapy for SR-GvHD (acute and chronic)1 2023 NCCN Guidelines®: Ruxolitinib is recommended as a category I treatment option for SR-GvHD (acute and chronic)2 |
“Transform the future for your patients with GvHD*3”
Hear from the Experts now!
VIDEO
For JAKAVI -GvHD Abbreviated prescribing information
For JAKAVI -GvHD Abbreviated prescribing information
*JAKAVI significantly reduced symptoms3
**therapy chosen by the investigators from a list of 10 commonly used options described in the protocol (extracorporeal photopheresis, low-dose methotrexate, mycophenolate mofetil, a mammalian target of rapamycin [mTOR] inhibitor [everolimus or sirolimus], infliximab, rituximab, pentostatin, imatinib, or ibrutinib).
EBMT, European Society for Blood and Marrow Transplantation; NCCN, National Comprehensive Cancer Network; GvHD, graft-versus-host disease
References
Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, Giebel S, Greinix H, Hazenberg MD, Kröger N, Mielke S. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. The Lancet Haematology. 2024 Feb 1;11(2):e147-59. available at https://www.thelancet.com/journals/lanhae/article/PIIS2352 3026(23)00342-3/abstract last accessed 12/8/2024
(NCCN Guidelines®) for Hematopoietic Cell Transplantation (HCT). V.3.2023 available at: https://www.nccn.org/professionals/physician_gls/pdf/hct.pdf Last accessed 26/3/2024
Summary of Product Characteristics (SmPC).Jakavi Tablets.Available at https://www.ema.europa.eu/en/documents/product-information/jakavi-epar-product-information_en.pdf Last Accessed 26/3/2024
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host diease. New England Journal of Medicine. 2021 Jul 15;385(3):228-38
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. New England Journal of Medicine. 2020 May 7;382(19):1800-10
Approved by Egyptian Drug Authority: HF0424OA4703/102025. Invalidation date: 17/12/2025.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg.
Image
|
HF0424OA4703/102025 17/12/2025 |
Adverse Events Reporting We encourage using the following Electronic reporting tool for reporting into the safety database directly: |